Fate Therapeutics (United States)
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
2016 · David T. Rodgers, Magdalena Mazagova, et al. · Proceedings of the National Academy of Sciences
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1
2017 · Giulia Schiroli, Samuele Ferrari, et al. · Science Translational Medicine
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
2020 · Frank Cichocki, Ryan Bjordahl, et al. · Science Translational Medicine